Sept 21 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES EXPANDED INVESTMENT AND EXCLUSIVE ACQUISITION OPTION AGREEMENT WITH FARAPULSE, INC..BOSTON SCIENTIFIC CORP - FARAPULSE IS PURSUING REGULATORY APPROVAL IN U.S..BOSTON SCIENTIFIC CORP - INTENDS TO INITIATE A PIVOTAL IDE TRIAL IN U.S.; IS PURSUING CE MARK APPROVAL IN EUROPE FOR ENDOCARDIAL ABLATION SYSTEM.
Full Article
July 21 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC RECEIVES FDA APPROVAL FOR NEXT-GENERATION WATCHMAN FLX™ LEFT ATRIAL APPENDAGE CLOSURE DEVICE.BOSTON SCIENTIFIC CORP - WILL IMMEDIATELY COMMENCE A LIMITED LAUNCH OF WATCHMAN FLX DEVICE IN U.S..
Full Article
May 21 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PRICES OFFERINGS OF COMMON STOCK AND MANDATORY CONVERTIBLE PREFERRED STOCK.PRICING OF CONCURRENT OFFERINGS OF 25,550,000 SHARES OF ITS COMMON AT A PRICE TO PUBLIC OF $34.25 PER SHARE.PRICED 8.75 MILLION SHARES OF ITS 5.50% MANDATORY CONVERTIBLE PREFERRED STOCK, SERIES A AT A PRICE OF $100.00 PER SHARE.
Full Article
May 14 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PRICES $1.7 BILLION OF SENIOR NOTES.BOSTON SCIENTIFIC - PUBLIC OFFERING CONSISTS OF $500.0 MILLION OF 1.900% NOTES DUE 2025 AND $1.2 BILLION OF 2.650% NOTES DUE 2030.
Full Article
Jan 14 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC - EXPECTS TO EXCEED PREVIOUS OUTLOOK FOR FY 2019 GAAP EARNINGS PER SHARE OF $0.72-$0.75 .BOSTON SCIENTIFIC - EXPECTS TO EXCEED PREVIOUS OUTLOOK FOR Q4 GAAP EARNINGS PER SHARE OF $0.22-$0.25 .SEES Q4 ADJUSTED EARNINGS PER SHARE $0.42-$0.45.BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR 2019.Q4 PRELIMINARY SALES $2.9 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.93 BILLION.Q4 EARNINGS PER SHARE VIEW $0.44, REVENUE VIEW $2.93 BILLION -- REFINITIV IBES DATA.ESTIMATES THAT IT WILL EXCEED ITS PREVIOUSLY ISSUED GUIDANCE FOR EARNINGS PER SHARE OF $0.22 TO $0.25 FOR Q4.ESTIMATES IT WILL EXCEED ITS PREVIOUSLY ISSUED GUIDANCE FOR EARNINGS PER SHARE OF $0.72 TO $0.75 FOR FY 2019, ON A GAAP PER SHARE BASIS.BOSTON SCIENTIFIC - ESTIMATES ADJUSTED EARNINGS WILL BE WITHIN PREVIOUSLY ISSUED GUIDANCE RANGE OF $1.55 TO $1.58 PER SHARE FOR FULL YEAR 2019.ESTIMATES Q4 ADJUSTED EARNINGS, EXCLUDING CERTAIN CHARGES (CREDITS), WILL BE WITHIN ITS PREVIOUSLY ISSUED GUIDANCE.FY2019 EARNINGS PER SHARE VIEW $1.57, REVENUE VIEW $10.76 BILLION -- REFINITIV IBES DATA.GENERATED PRELIMINARY FY 2019 SALES OF ABOUT $10.74 BILLION.
Full Article
Nov 6 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PRICES €900,000,000 OF SENIOR NOTES.BOSTON SCIENTIFIC CORP - PRICING OF OFFERING OF EUR 900 MILLION OF 0.625% NOTES DUE 2027.
Full Article
Aug 19 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES FDA APPROVAL OF IMAGEREADY™ MRI FOR VERCISE GEVIA™ DEEP BRAIN STIMULATION SYSTEM.BOSTON SCIENTIFIC - VERCISE GEVIA DEEP BRAIN STIMULATION SYSTEM, VERCISE CARTESIA DIRECTIONAL LEAD IS DESIGNED TO TREAT PARKINSON'S DISEASE SYMPTOMS.
Full Article
Aug 19 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC - SUBMITTED BORROWING REQUEST FOR $2.0 BILLION TO BE FUNDED ON AUG 19.BOSTON SCIENTIFIC CORP - FUNDS FROM DRAWDOWN WILL BE USED TO PARTIALLY FINANCE BOSTON SCIENTIFIC'S ACQUISITION OF BTG PLC.BOSTON SCIENTIFIC - BORROWINGS UNDER TWO-YEAR DELAYED DRAW TERM LOAN CREDIT FACILITY WILL MATURE TWO YEARS FROM DATE OF CLOSING OF BTG ACQUISITION.BOSTON SCIENTIFIC - BORROWINGS UNDER THREE-YEAR DELAYED DRAW TERM LOAN CREDIT FACILITY WILL MATURE THREE YEARS FROM DATE OF CLOSING OF BTG ACQUISITION.BOSTON SCIENTIFIC - EXPECTS TO COMPLETE ANNOUNCED SALE OF GLOBAL EMBOLIC MICROSPHERES PORTFOLIO TO VARIAN MEDICAL SYSTEMS.
Full Article
Aug 7 (Reuters) - Boston Scientific Corp ::BTG, BOSTON SCIENTIFIC CONFIRM TRANSACTION RECEIVED MERGER CONTROL CLEARANCE FROM US FEDERAL TRADE COMMISSION.DEAL WITH BOSTON SCIENTIFIC ALSO CLEARED IN SPAIN, AUSTRIA.
Full Article
July 2 (Reuters) - BTG ::BTG - ON 1 JULY, BOSTON SCIENTIFIC SIGNED AGREEMENT FOR SALE OF EXISTING DRUG-ELUTING AND BLAND EMBOLIC MICROSPHERE BUSINESS.
Full Article
Earnings vs. 
Estimates